We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04201262




Registration number
NCT04201262
Ethics application status
Date submitted
11/12/2019
Date registered
17/12/2019
Date last updated
14/04/2021

Titles & IDs
Public title
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Scientific title
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Secondary ID [1] 0 0
CHAMPION-NMO-307
Secondary ID [2] 0 0
ALXN1210-NMO-307
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neuromyelitis Optica 0 0
Neuromyelitis Optica Spectrum Disorder 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Neurological 0 0 0 0
Other neurological disorders
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Ravulizumab

Experimental: Ravulizumab - During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).
After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first.


Other interventions: Ravulizumab
Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time To First Adjudicated On-Trial Relapse
Timepoint [1] 0 0
Baseline, up to 2 years (end of the Primary Treatment Period)
Secondary outcome [1] 0 0
Incidence Of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, And TEAEs Leading To Study Drug Discontinuation
Timepoint [1] 0 0
Baseline, up to 2 years (end of the Primary Treatment Period)
Secondary outcome [2] 0 0
Adjudicated On-Trial Annualized Relapse Rate
Timepoint [2] 0 0
Baseline, up to 2 years (end of the Primary Treatment Period)
Secondary outcome [3] 0 0
Clinically Important Worsening In Expanded Disability Status Scale
Timepoint [3] 0 0
Baseline, up to 2 years (end of the Primary Treatment Period)

Eligibility
Key inclusion criteria
1. Anti-aquaporin-4 antibody-positive and a diagnosis of NMOSD as defined by the 2015
international consensus diagnostic criteria.

2. At least 1 attack or relapse in the last 12 months prior to the Screening Period.

3. Expanded Disability Status Scale score =7.

4. Participants who enter the study receiving supportive immunosuppressive therapy must
be on a stable dosing regimen of adequate duration prior to Screening.

5. Body weight =40 kilograms.

6. Contraceptive use by men or women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. History of neisseria meningitidis infection.

2. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody
titer).

3. Previously or currently treated with a complement inhibitor.

4. Use of rituximab or mitoxantrone within 3 months prior to Screening.

5. Use of IV immunoglobulin within 3 weeks prior to Screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Clinical Study Site - Camperdown
Recruitment hospital [2] 0 0
Clinical Study Site - New Lambton Heights
Recruitment hospital [3] 0 0
Clinical Study Site - Parkville
Recruitment hospital [4] 0 0
Clinical Study Site - Fitzroy
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
Austria
State/province [17] 0 0
Wien
Country [18] 0 0
Canada
State/province [18] 0 0
British Columbia
Country [19] 0 0
Canada
State/province [19] 0 0
Edmonton
Country [20] 0 0
Denmark
State/province [20] 0 0
Aarhus
Country [21] 0 0
France
State/province [21] 0 0
Lyon
Country [22] 0 0
France
State/province [22] 0 0
Montpellier
Country [23] 0 0
France
State/province [23] 0 0
Nîmes
Country [24] 0 0
France
State/province [24] 0 0
Strasbourg
Country [25] 0 0
Germany
State/province [25] 0 0
Berlin
Country [26] 0 0
Germany
State/province [26] 0 0
Dresden
Country [27] 0 0
Germany
State/province [27] 0 0
Leipzig
Country [28] 0 0
Germany
State/province [28] 0 0
Muenchen
Country [29] 0 0
Italy
State/province [29] 0 0
Gallarate
Country [30] 0 0
Italy
State/province [30] 0 0
Napoli
Country [31] 0 0
Italy
State/province [31] 0 0
Orbassano
Country [32] 0 0
Italy
State/province [32] 0 0
Palermo
Country [33] 0 0
Italy
State/province [33] 0 0
Roma
Country [34] 0 0
Japan
State/province [34] 0 0
Chiba
Country [35] 0 0
Japan
State/province [35] 0 0
Fukuoka-shi
Country [36] 0 0
Japan
State/province [36] 0 0
Kawagoe-shi
Country [37] 0 0
Japan
State/province [37] 0 0
Niigata-shi
Country [38] 0 0
Japan
State/province [38] 0 0
Sendai-shi
Country [39] 0 0
Japan
State/province [39] 0 0
Sendai
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Goyang-si
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Seoul
Country [42] 0 0
Poland
State/province [42] 0 0
Katowice
Country [43] 0 0
Spain
State/province [43] 0 0
Baracaldo
Country [44] 0 0
Spain
State/province [44] 0 0
Barcelona
Country [45] 0 0
Spain
State/province [45] 0 0
Madrid
Country [46] 0 0
Spain
State/province [46] 0 0
Malaga
Country [47] 0 0
Spain
State/province [47] 0 0
Valencia
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Liverpool
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Alexion Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for
the treatment of adult participants with NMOSD.
Trial website
https://clinicaltrials.gov/show/NCT04201262
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications